Heranba Industries Ltd Q1 FY26 – Sales ₹452 Cr (+53%), PAT ₹6 Cr (-64%), EPS ₹1.52. Agrochemicals or Agro-Comedies?
1. At a Glance
Heranba is that neighbour who keeps buying new farmland, new tractors, new sprinklers — but when you ask about harvest, he quietly serves you Maggi. Q1 FY26 revenue shot up 53% YoY to ₹452 Cr, but profit crashed 64% to ₹6 Cr. EPS = ₹1.52. Market cap ₹1,279 Cr, debt ₹349 Cr, ROCE gasping at 4.4%. Agrochemical industry is about killing pests, but in Heranba’s case, the pest seems to be profitability.
2. Introduction
Once upon a time (1994), Heranba entered agrochemicals with dreams of becoming the “UPL of the future.” They mastered pyrethroids, dominated intermediates, and expanded like a politician’s relatives post-elections.
Fast forward: they serve 74 countries, boast 10,000 dealers, own 6 factories, 3 R&D centres, 24 depots. Product portfolio? From insecticides to herbicides, fungicides, growth regulators. Brand names? Ginee, Dinomite, Tagda, Troller — sound more like WWE wrestlers than crop protectors.
But here’s the newsroom headline: despite massive capacity expansion (Saykha, Sarigam), Heranba is stuck in a bad sitcom where revenue keeps rising but profits are missing from the script. FY25 net profit collapsed to ₹2 Cr from ₹104 Cr just two years back.
Question for readers: would you trust a company selling pesticides named “Tagda” when its own P&L looks so weak?
3. Business Model – WTF Do They Even Do?
Think of Heranba as a three-layer pesticide cake:
Intermediates: They cook up chemicals like CMAC, High CIS CMA, bromobenzenes. Sounds fancy, but mostly go into captive use for making higher-margin products.
Technicals: The “real” act — cypermethrin, deltamethrin, glyphosate, tricyclazole. Basically, the names you see when farmers complain about price hikes.
Formulations: Branded products like Hauris, Loranta, Glory. Launched newer ones — Ginee, Dinomite, Heragen, Tagda. Imagine a pesticide ad with WWE commentary: “Tagda aa gaya, weeds bhagaa gaya.”
Revenue split has shifted: Technicals now 50% vs 67% two years ago, while Formulations climbed to 50%. Which means — less B2B bulk, more farmer-facing small packs. More brand risk, more dealer politics, more working capital stress.
4. Financials Overview
Source table
Metric
Latest Qtr (Q1 FY26)
YoY Qtr (Q1 FY25)
Prev Qtr (Q4 FY25)
YoY %
QoQ %
Revenue
452
296
335
52.7%
35.0%
EBITDA
31.2
40.3
-14.5
-22.5%
Turned positive
PAT
6.1
16.6
-41.7
-63.3%
N/A
EPS (₹)
1.52
4.19
-10.37
-63.7%
N/A
Commentary: Sales doubled, profits halved. EBITDA margin collapsed to 6.9% vs ~13% a year ago. It’s like hosting a crowded wedding where the food runs out before the main course. Annualised EPS = ₹6. CMP ₹320 = P/E 53 (if you’re generous; if you’re strict, P/E = N/A since FY25 was loss-making).
5. Valuation Discussion – Fair Value Range
Three ways to expose the joke:
P/E Method: EPS annualised ~₹6. Industry P/E ~32. → Fair value = 15×–25× = ₹90–₹150.
EV/EBITDA Method: FY25 EBITDA ~₹89 Cr. EV ~₹1,573 Cr. EV/EBITDA = 17.7. Peer average = 12–15. → Fair EV = 12×89 to 15×89 = ₹1,070–₹1,335 Cr. Per share = ₹265–₹330.
